Case Study: Medical Writing in a Complex Clinical Development Program

Clinical Research NewsMay 17, 2026

When clinical development moves beyond established science

A global pharmaceutical company initiated a clinical development program to explore an existing compound in a new indication within the field of rare neglected tropical diseases (NTD ). While early data indicated potential, the development context was highly uncertain.

The indication had no validated clinical endpoints and limited precedent in formal clinical trials. At the same time, the program progressed rapidly toward late-phase development, requiring a Phase 3 clinical trial protocol and regulatory documentation that could meet expectations from global Health Authorities, including EMA, US FDA and WHO.

The challenge was not only scientific. It was structural. Multiple documents evolved in parallel, regulatory feedback required continuous updates and alignment across stakeholders became increasingly difficult to maintain.

Challenges: managing scientific uncertainty and constant change

The medical writing effort was shaped by a set of challenges that go beyond what is typically expected.

First, the absence of standardized endpoints meant that the clinical team could not rely on existing frameworks. Each element of the trial design required justification, supported by scientific evidence and translated into a clear regulatory narrative.

Second, the program involved multiple rounds of scientific advice with different agencies. Feedback from EMA, FDA and WHO introduced evolving and sometimes diverging expectations. Each update had to be reflected consistently across the clinical trial protocol, briefing packages and supporting documents.

Third, the volume and interdependency of documents created a high risk of inconsistencies. Changes made in one document could impact several others, requiring continuous oversight to maintain alignment.

Finally, the internal team operated under significant time and resource constraints. Key scientific input was not always readily available in a structured format, requiring additional effort to build a complete and coherent documentation package.

Without strong coordination, the risk of inconsistencies, delays and regulatory misalignment was significant.

Approach: extending the role of medical writing

We assigned a lead medical writer who took full ownership of the documentation landscape. In this case, the role extended well beyond traditional medical writing responsibilities.

Scientific contribution beyond documentation:
From the outset, we contributed to the scientific foundation of the program. Rather than relying solely on provided input, we conducted literature research, developed scientific background sections and verified assumptions used in the clinical and regulatory strategy. This ensured that all documents were grounded in a consistent and defensible scientific rationale.
End-to-end ownership and alignment across documents
The medical writer maintained oversight of the clinical trial protocol, multiple scientific advice briefing packages and additional strategic documents. Each update driven by regulatory feedback was implemented consistently across all materials, reducing the risk of conflicting messages.
Active management of complexity and decision tracking
To maintain control in a highly iterative environment, we implemented structured tracking of discussions, decisions and rationale. This allowed the team to maintain continuity, avoid revisiting previously resolved topics and ensure that all stakeholders worked from the same understanding.
Alignment across global health authorities, including WHO
Beyond EMA and US FDA interactions, the program required alignment with WHO expectations, which introduced additional complexity. We ensured that documentation remained coherent across these different regulatory perspectives, each with its own priorities.
Collaboration with cross-functional experts and internal SGS teams
The medical writer worked closely with clinical, regulatory and strategic stakeholders, acting as a central point of coordination. In addition, we involved internal team members for quality control and consistency checks, ensuring that all documents met high standards of accuracy, clarity and compliance.

Impact: ensuring consistency and control across global regulatory interactions

A structured and proactive approach enabled the clinical team to maintain control in a highly complex program. The absence of established endpoints led to continuous refinement of the trial design, with varying expectations across stakeholders and global health authorities, including EMA, FDA, and WHO. Throughout multiple iterations and interactions, the documentation remained consistent, accurate and aligned.

This level of alignment was supported by medical writers with strong scientific backgrounds, capable of conducting literature research, validating assumptions and translating complex data into a coherent regulatory narrative. This allowed the internal team to focus on key scientific and strategic decisions.

Redefining the role of a medical writing services CRO in complex clinical trials

This case illustrates how the role of a medical writing services CRO can extend far beyond standard document preparation in clinical research and drug development. In complex clinical trial dossiers, medical writing becomes a central function for maintaining alignment and ensuring progress.

By combining scientific expertise, full ownership of document creation and structured collaboration with cross-functional teams, we support sponsors in managing complexity and reducing risk throughout the development process. Depending on program needs, this support can be delivered through full outsourcing or staffing as part of your team, providing the flexibility required to match the complexity and pace of development.

For pharmaceutical and biotech companies operating in high-risk or innovative areas, this level of support helps reduce uncertainty, improve alignment and accelerate progress toward key development milestones.